Time Commitment: 5 hours over 56 days
Credits Available: 5.0 AMA PRA Category 1 Credit™ & 5 MOC points

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login



Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Oncology, Radiology, Urology

Megan Fonteno

MD Anderson
Sarcoma/Melanoma Clinical Pharmacist

My name is Megan Fonteno, PharmD. I completed two years of post graduate school residency at Columbus Regional hospital for year one and University of Utah’s Huntsman Cancer Institute for my oncology second year. I attended Auburn University for Pharmacy School and currently practice as a Melanoma/Sarcoma Pharmacist Specialist at MD Anderson Cancer Center.